A detailed history of Brown Brothers Harriman & CO transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Brown Brothers Harriman & CO holds 4,394 shares of SRPT stock, worth $573,417. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,394
Previous 4,370 0.55%
Holding current value
$573,417
Previous $690,000 20.58%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$124.33 - $156.75 $2,983 - $3,762
24 Added 0.55%
4,394 $548,000
Q4 2023

Feb 12, 2024

SELL
$67.31 - $124.76 $6,259 - $11,602
-93 Reduced 2.08%
4,370 $421,000
Q3 2023

Nov 13, 2023

BUY
$102.5 - $123.59 $9,532 - $11,493
93 Added 2.13%
4,463 $541,000
Q2 2023

Aug 07, 2023

SELL
$106.4 - $157.19 $638,400 - $943,140
-6,000 Reduced 57.86%
4,370 $500,000
Q2 2020

Aug 13, 2020

SELL
$93.0 - $171.7 $279,000 - $515,099
-3,000 Reduced 22.44%
10,370 $1.66 Million
Q4 2019

Feb 14, 2020

SELL
$76.53 - $135.58 $229 - $406
-3 Reduced 0.02%
13,370 $1.73 Million
Q3 2019

Nov 14, 2019

SELL
$72.81 - $156.91 $364 - $784
-5 Reduced 0.04%
13,373 $1.01 Million
Q2 2019

Aug 14, 2019

BUY
$112.21 - $151.95 $897 - $1,215
8 Added 0.06%
13,378 $2.03 Million
Q3 2018

Nov 14, 2018

SELL
$115.31 - $161.51 $1.38 Million - $1.94 Million
-12,000 Reduced 47.3%
13,370 $2.16 Million
Q1 2018

May 14, 2018

SELL
$54.02 - $82.27 $162,060 - $246,810
-3,000 Reduced 10.57%
25,370 $1.88 Million
Q4 2017

Feb 14, 2018

SELL
$47.64 - $56.75 $142,920 - $170,250
-3,000 Reduced 9.56%
28,370 $1.58 Million
Q2 2017

Aug 14, 2017

BUY
N/A
31,370
31,370 $1.06 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $11.4B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Brown Brothers Harriman & CO Portfolio

Follow Brown Brothers Harriman & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

News

Stay updated on Brown Brothers Harriman & CO with notifications on news.